Adherence and persistence in patients with type 2 diabetes initiating once-weekly versus once-daily injectable GLP-1 RAs in US clinical practice (STAY study)
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Acknowledgements
This is a highlights summary of an oral session given at the Virtual EASD Annual Meeting 2021 and presented by:
Prof. William Polonsky
Behavioral Diabetes Institute and University of California
San Diego, CA, USA
The content is produced by Infomedica. The presenting authors of the original session had no part in the creation of this conference highlights summary.
References
1. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296-310.
2. Uzoigwe C, Liang Y, Whitmire S, Paprocki Y. Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting. Diabetes Ther. 2021;12(5):1475-1489.
Related content
Related abstracts
Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States.
Weiss T, Carr RD, Pal S, et al.
Patient Prefer Adherence. 2020;14:2337-2345.
Patient preferences for glucagon-like peptide 1 receptor-agonist treatment attributes.
Thieu VT, Robinson S, Kennedy-Martin T, et al.
Patient Prefer Adherence. 2019;13:561-576.
Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom.
Qin L, Chen S, Flood E, et al.
Diabetes Ther. 2017;8(2):335-353.
